Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016', provides in depth analysis on Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - The report reviews Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics and enlists all their major and minor projects - The report assesses Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Overview 6 Therapeutics Development 7 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Stage of Development 7 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Therapy Area 8 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Indication 9 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Companies 13 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Universities/Institutes 15 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Companies Involved in Therapeutics Development 24 Galectin Therapeutics, Inc. 24 PepTx, Inc. 25 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Drug Profiles 26 CNC-225 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 GM-CT-01 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 GRMD-02 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Monoclonal Antibody to Inhibit Galectin-1 for B-Cell Non-Hodgkin Lymphoma - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 PTX-013 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Dormant Projects 44 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Discontinued Products 45 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Featured News & Press Releases 46 Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension 46 May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis 46 May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis 47 May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference 48 Feb 24, 2016: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis 48 Jan 07, 2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website 49 Nov 11, 2015: Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting 51 Oct 19, 2015: Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda in Patients With Metastatic Melanoma 52 Sep 24, 2015: Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 53 Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis 53 Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 54 Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH 55 Jun 29, 2015: Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis 55 May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 57 Mar 24, 2015: Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Galectin Therapeutics, Inc., H1 2016 24 Pipeline by PepTx, Inc., H1 2016 25 Dormant Projects, H1 2016 44 Discontinued Products, H1 2016 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
